MedTrace Logo

Metabolomics Study on Intensive Care Acquired Muscle Weakness in Polytrauma

NCT03819959 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2020-10-06

No results posted yet for this study

Summary

In this mono-center pilot trial, polytrauma patients admitted to intensive care will be included. Investigators are going to take blood and muscle samples at respecified time points to do metabolic, histological and molecular testing.

Aim of the study is to investigate (1) changes of the blood metabolome in patients with ICUAW (intensive care unit acquired weakness) and (2) identify metabolic components who are responsible for ICUAW or can be used as marker for ICUAW.

Conditions

  • Metabolomics
  • Critical Care
  • Critical Illness
  • Critical Illness Myopathy
  • Critical Illness Polyneuropathy
  • Intensive Care (ICU) Myopathy
  • Muscle Weakness

Sponsors & Collaborators

  • Helmholtz Zentrum München

    collaborator INDUSTRY

  • Technical University of Munich

    lead OTHER

Principal Investigators

  • Stefan J Schaller, MD, MHBA · Technical University of Munich

  • Hennig Wackerhage, PhD · Technical University of Munich

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-24
Primary Completion
2020-04-22
Completion
2020-04-22

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03819959 on ClinicalTrials.gov